PLX
Protalix BioTherapeutics Inc.
Halal Rating :
Last Price
$2.21
Last updated:
Market Cap
-
7D Change
0.23%
1 Year Change
40.45%
Company Overview
Industries
Exchange
Next Earnings Date
Protalix BioTherapeutics Inc. is a biopharmaceutical company focused on the development, production, and commercialization of recombinant therapeutic proteins primarily for the treatment of rare genetic diseases. Their proprietary ProCellEx® platform technology enables the production of proteins through plant cell-based expression systems. The company's lead product is ELFABRIO® (pegunigalsidase alfa-iwxj), approved for the treatment of adult patients with Fabry disease.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $17.96m | $13.97m | - | - | 0.00% | 0.00% |
| June 30, 2024 | $13.47m | $15.9m | - | - | 0.00% | 0.00% |
| March 31, 2024 | $3.75m | $8.6m | - | - | 0.00% | 0.00% |
Company Impact
Help us evaluate Protalix BioTherapeutics Inc.'s impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.